Ovarian Cancer

Mira Dx(TM) Dismisses Flawed Study as "Puzzling," and "Comparing Apples and Oranges"

Published in Cancer Weekly, March 29th, 2011

2011 MAR 29 -- Data recently presented at the Society of Gynecology Oncology calling into question Mira Dx's PreOvar® test is "so flawed that is surprising it was even considered for presentation," says the top executive of Mira Dx.

Martin Verhoef, President and CEO of Mira DX, said the study presented by Dr. Andrew Berchuck "is puzzling because it makes claims based on inapposite data. This is really a classic case of comparing apples and oranges."

PreOvar® is a test for the assessment of risk for ovarian cancer in specific female populations that are at increased risk for the disease. The PreOvar® test is based on...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2011-03-29)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry